Evidence map›Paper›PMID 38507030›Full record

Observational studyMolecular neurobiology2024

High Frequency of Autoantibodies in COVID-19 Patients with Central Nervous System Complications: a Multicenter Observational Study.

Jingfang Lin, Dong Zheng, Decai Tian, Pei Zheng, Hongya Zhang, Chuo Li, Chunliang Lei, Fudong Shi, Honghao Wang

Abstract readMulticenter StudyObservational Study
PubMed Publisher
In one paragraph

Observational study in Molecular neurobiology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Jingfang LinDepartment of Neurology, Guangzhou First People's Hospital, South China University of Technology, Guangzhou, China.
Dong ZhengDepartment of Neurology, The Affiliated Brain Hospital of Guangzhou Medical University, Guangzhou, China.
Decai TianDepartment of Neurology, Beijing Tiantan Hospital, Capital Medical University, Beijing, China.
Pei ZhengCenter for Neurological Diseases, China National Clinical Research Center for Neurological Diseases, Beijing Tiantan Hospital, Capital Medical University, Beijing, China.
Hongya ZhangDepartment of Neurology, Shenzhen University General Hospital, Shenzhen, China.
Chuo LiDepartment of Neurology, Eight People's Hospital of Guangzhou, Guangzhou, China.
Chunliang LeiEight People's Hospital of Guangzhou, Guangzhou, China.
Fudong Shi *Department of Neurology, Beijing Tiantan Hospital, Capital Medical University, Beijing, China.
Honghao Wang *Department of Neurology, Guangzhou First People's Hospital, South China University of Technology, Guangzhou, China. wang_whh@163.com.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

We present a panel of central nervous system (CNS) complications associated with coronavirus disease 2019 (COVID-19) and their clinical characteristics. We aim to investigate associations between neurological autoantibodies and COVID-19 patients with predominant CNS complications. In this retrospective multi-center study, we analyze neurologic complications associated with COVID-19 patients from Dec. 2022 to Feb. 2023 at four tertiary hospitals in China. CSF and/or serum in the enrolled patients were tested for autoantibodies using tissue-based assays (TBAs) and cell-based assays (CBAs). A total of 34 consecutive patients (median age was 40.5 years [range 15-83], 50% were female) were enrolled. CNS syndromes included encephalitis (n=15), encephalopathies (n=6), meningoencephalitis (n=3), ADEM (n=2), depression (n = 2), Alzheimer's disease (n=2), Parkinson disease (n=1), and central nervous system vasculitis (n=1). Twenty-eight specimens (of 44 tested; 11/27 [40.7%] CSF, 13/17 [76.5%] serums) were confirmed by TBAs to be autoantibodies positive. However, only a few autoantibodies (1 with MOG and 1 with NMDAR) were detected by CBAs assays. Twenty-four patients received immunotherapy. After a mean time of 7.26 months of follow-up, 75.8% (25/33) of patients had good outcome (mRS score ≤2). Although no significant difference was observed between the two groups, the proportion of positive CSF autoantibodies in the poor outcomes group was higher than that in the good outcomes group (57.1% vs 31.5%, P = 0.369). Autoantibodies were frequently observed in COVID-19-associated CNS complications. The identification of these autoantibody-positive COVID-19 cases is important as they respond favorably to immunotherapy.

Indexed as

AutoantibodiesCentral Nervous System DiseasesCOVID-19AdolescentAdultAgedAged, 80 and overFemaleHumansMaleMiddle AgedRetrospective StudiesSARS-CoV-2Young AdultAutoantibodiesAutoantibodiesCNS complicationsCOVID-19PrognosisTreatment

Identifiers

PMID38507030

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.